Mesothelin

Mesothelin is a protein found on the surface of normal mesothelial cells (the thin lining around the lungs, abdomen, and heart) that is produced in much higher amounts by mesothelioma and some other cancers. A soluble form of this protein can be measured in the blood and is used as a biomarker to help support a mesothelioma diagnosis, track response to treatment, and watch for recurrence.

Origin

The word comes from "mesothelium," the membrane where the protein is normally expressed, combining the Greek roots "mesos" (middle) and "thele" (covering layer). Mesothelin was first identified in 1992 by Ira Pastan and colleagues at the National Cancer Institute using a monoclonal antibody (K1) that reacted with ovarian cancer and mesothelioma cells.

Significance in Asbestos Context

For patients with suspected or confirmed mesothelioma, mesothelin most often appears in the form of a blood test called the Mesomark® assay, which measures Soluble Mesothelin-Related Peptides (SMRP). It isn't used alone to diagnose mesothelioma. Biopsy and pathology remain the gold standard, but an elevated level can support the diagnosis and, when followed over time, can help your oncology team judge whether treatment is working or whether the disease is returning.

The test works best in the epithelioid subtype of mesothelioma. Sarcomatoid and biphasic mesotheliomas often produce normal or only mildly elevated levels, so a normal result does not rule out the disease. Mesothelin can also be elevated in ovarian cancer, pancreatic cancer, some lung cancers, and in people with reduced kidney function, which is why the result must always be interpreted alongside imaging and pathology.

For a legal claim, serial mesothelin measurements in your medical record can help document when your disease became active and how it has progressed, information that may matter for damages, for proving the link to past asbestos exposure, and for some asbestos bankruptcy trust submissions that accept biomarker data as part of the supporting medical package. Defense experts often argue that mesothelin lacks the sensitivity and specificity to stand on its own, so your legal team will typically pair these results with biopsy reports, immunohistochemistry findings, and exposure history rather than relying on the blood test alone.

Example Sentence

"The oncologist ordered serial Mesomark® tests every three months to monitor the patient's mesothelin levels alongside CT imaging, and the rising trend helped confirm that the disease was progressing despite chemotherapy."

Related Terms

Soluble Mesothelin-Related Peptides (SMRP), Mesomark® Assay, Biomarker, Epithelioid Mesothelioma, Immunohistochemistry (IHC), Fibulin-3

Notes

• Ask your oncologist whether a Mesomark® (SMRP) blood test has been ordered, and request copies of every result so you have a documented trend over time.
• Understand the limits before drawing conclusions: a normal mesothelin level does not rule out mesothelioma, especially for sarcomatoid or biphasic subtypes, and an elevated level is not by itself a diagnosis.
• If you have kidney disease or another known cancer, mention this to your doctor. These conditions can raise mesothelin levels and affect how the result is interpreted.
• Keep all laboratory reports showing mesothelin values together with your pathology and imaging reports; attorneys and asbestos trust administrators may request these to support claims and rebut alternative-cause arguments.
• Ask whether you are a candidate for clinical trials targeting mesothelin (such as CAR-T therapy, anetumab ravtansine, or other antibody-based treatments), as this protein is an active area of mesothelioma drug development.